New Study Proves the FDA Is Actively Suppressing Information About the Harmful Effects of Gardasil

Young, healthy women who experience amenorrhea, ovarian failure, and infertility have likely been damaged by Merck’s HPV vaccine. A new study published in the Journal of Toxicology and Environmental Health analyzed data on pregnancy outcomes, comparing women who received an HPV vaccine with those who did not. The data analysis is titled, “A lowered probability of pregnancy in females in the USA aged 25 who received a human papillomavirus vaccine injection.”

The study, uninfluenced by pharmaceutical money, analyzed data on 8 million women aged 25-29 living in the U.S. from 2007 and 2014. According to the analysis, conception rates would have fallen by 2 million if 100 percent of the females in the study would have received the HPV vaccine. The study warns that the HPV vaccine has a negative influence on fertility and more research is “warranted.”

Despite mounting evidence of harm, Merck seeks to fast-track Gardasil on new age group

Despite these grave concerns, the Food and Drug Administration (FDA) is currently fast tracking the process by which the Gardasil-9 is approved for use in women and men ages 27 to 45. Merck’s application for approval has been granted priority review, and is scheduled for an approval date of October 6, 2018. So, much important information about Gardasil’s risks will be suppressed as the FDA moves quickly on behalf of Merck’s business interests.

More